Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-03-23FDA Approved: TORISEL — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for TORISEL (temsirolimus) from Wyeth Pharmaceuticals (a Pfizer subsidiary).
-
FDA approval · 2017-12-22FDA Approved: NEXAVAR — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Nexavar (sorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2017-11-16FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
FDA has approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals. This entry documents the supple…
-
FDA approval · 2017-09-14FDA Approved: MVASI — Original Application (Amgen, Inc)
The FDA approved MVASI (bevacizumab-awwb) from Amgen as a biosimilar to Avastin, marking the original application granting U.S. approval for…
-
FDA approval · 2017-05-31FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) submitted by Novartis Pharmaceuticals Corporation. The ap…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-10-12FDA Approved: ZORTRESS — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for ZORTRESS (everolimus) submitted by Novartis Pharmaceuticals Corporation. The action likely a…
-
EMA approval · 2016-07-22Two new medicines for advanced kidney cancer
The EMA announced two new medicines approved for advanced kidney cancer, expanding treatment options for this disease.
-
FDA approval · 2016-06-16FDA Approved: INLYTA — Supplemental Application (U.S. Pharmaceuticals)
FDA approved a supplemental application for INLYTA (axitinib) submitted by U.S. Pharmaceuticals. This action updates the drug’s labeling for…
-
FDA approval · 2016-05-20FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) filed by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2016-03-30FDA Approved: INLYTA — Supplemental Application (U.S. Pharmaceuticals)
The FDA approved a supplemental application for INLYTA (axitinib) submitted by U.S. Pharmaceuticals.
-
FDA approval · 2015-09-22FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals, signaling an update to the dru…
-
FDA approval · 2015-05-06FDA Approved: PROLEUKIN — Supplemental Application (Iovance Biotherapeutics, Inc)
The FDA approved a supplemental application for PROLEUKIN (aldesleukin) filed by Iovance Biotherapeutics, Inc, indicating an updated regulat…
-
FDA approval · 2015-04-24FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
FDA approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals.
-
FDA approval · 2014-12-19FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
The FDA approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals.
-
FDA approval · 2014-11-18FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2014-10-07FDA Approved: TORISEL — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for TORISEL (temsirolimus) from Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
-
FDA approval · 2014-04-07FDA Approved: TORISEL — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for Torisel (temsirolimus) from Wyeth Pharmaceuticals (a Pfizer unit).
-
FDA approval · 2013-11-27FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2013-09-16FDA Approved: INLYTA — Supplemental Application (U.S. Pharmaceuticals)
The FDA approved a supplemental application for INLYTA (axitinib) submitted by U.S. Pharmaceuticals.
-
FDA approval · 2013-08-30FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
The FDA overview notes a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals. The submission status is …
-
FDA approval · 2012-08-29FDA Approved: AFINITOR DISPERZ — Original Application (Novartis Pharmaceuticals Corporation)
FDA approves AFINITOR DISPERZ (everolimus) under an Original Application for a dispersible tablet formulation.
-
FDA approval · 2012-08-24FDA Approved: NEXAVAR — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Nexavar (sorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2012-05-30FDA Approved: TORISEL — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for Torisel (temsirolimus) filed by Wyeth Pharmaceuticals (Pfizer).
-
FDA approval · 2012-04-26FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS approval · 2012-03-09Clinical Trial Update: Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Pfizer's sunitinib (SU011248) has been approved for marketing for use in cytokine-refractory metastatic renal cell carcinoma.